Literature DB >> 12918763

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.

Daniel S Morris1, Michael P Gavin, Roger D Sturrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12918763     DOI： 10.1007/0-306-48382-3_112

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  4 in total

Review 1.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

3.  Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.

Authors:  Bahram Bodaghi; Gael Gendron; Bertrand Wechsler; Céline Terrada; Nathalie Cassoux; Du Le Thi Huong; Claire Lemaitre; Christine Fradeau; Phuc LeHoang; Jean-Charles Piette
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

4.  Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Olga Kaloudi; Emanuele Cassarà; Massimo Susini; Ivo Lenzetti
Journal:  Biologics       Date:  2011-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.